Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) Research & Development (2016 - 2025)

Apyx Medical (APYX) has disclosed Research & Development for 15 consecutive years, with $971000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 14.6% year-over-year to $971000.0, compared with a TTM value of $3.4 million through Dec 2025, down 33.33%, and an annual FY2025 reading of $3.4 million, down 33.33% over the prior year.
  • Research & Development was $971000.0 for Q4 2025 at Apyx Medical, up from $801000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $1.7 million in Q3 2023 and bottomed at $801000.0 in Q3 2025.
  • Average Research & Development over 5 years is $1.2 million, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw Research & Development soared 61.83% in 2023, then tumbled 42.45% in 2025.
  • Year by year, Research & Development stood at $947000.0 in 2021, then surged by 32.52% to $1.3 million in 2022, then increased by 11.79% to $1.4 million in 2023, then fell by 18.96% to $1.1 million in 2024, then dropped by 14.6% to $971000.0 in 2025.
  • Business Quant data shows Research & Development for APYX at $971000.0 in Q4 2025, $801000.0 in Q3 2025, and $824000.0 in Q2 2025.